Rehabilitation Unit, Kyoto University Hospital, Kyoto, Japan.
Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, 54, Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan; Department of Clinical Laboratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Transplant Cell Ther. 2022 Sep;28(9):602.e1-602.e7. doi: 10.1016/j.jtct.2022.06.011. Epub 2022 Jun 19.
During clinical courses involving treatment with allogeneic hematopoietic stem cell transplantation (allo-HSCT), multidisciplinary patient assessment including physical function is indispensable, and quantitative skeletal muscle loss is a poor prognostic marker. Deteriorating quality of muscle from intramuscular adipose tissue degeneration can be important as well, because many patients are cachexic or sarcopenic before allo-HSCT, although this approach has not yet been used in such patients. We conducted this retrospective cohort study to evaluate the quality as well as quantity of skeletal muscle using computed tomography (CT) scans. The psoas muscle mass index (PMI) and radiographic density (RD) calculated by cross-sectional area and averaged CT values of the psoas major muscle at the umbilical level were used to determine the quantity and quality of muscle, respectively. A total of 186 adult patients, ranging in age from 17 to 68 years (median, 49 years), were included in this study, with 46 (24.7%) assigned to the lower PMI group and 49 (26.3%) assigned to the lower RD group. Low RD was identified as an independent risk factor for poor overall survival after allo-HSCT (adjusted hazard ratio [HR], 2.54; P < .01), whereas PMI was not significant. Decreased RD along with a reduced 6-min walking distance before transplantation were significant factors in increased nonrelapse mortality (HR, 2.69; P = .01). This study is the first to suggest the use of a qualitative skeletal muscle index to serve as a prognostic indicator following allo-HSCT. RD should be included in pretransplantation screening parameters, and approaches that include rehabilitation focused on improving both muscle quality and quantity may improve the prognosis of allo-HSCT.
在涉及异基因造血干细胞移植(allo-HSCT)治疗的临床课程中,多学科的患者评估包括身体功能是必不可少的,定量的骨骼肌损失是一个不良预后标志物。肌肉内脂肪组织变性引起的肌肉质量恶化也很重要,因为许多患者在 allo-HSCT 之前就已经出现恶病质或肌肉减少症,尽管这种方法尚未在这些患者中使用。我们进行了这项回顾性队列研究,使用计算机断层扫描(CT)扫描评估骨骼肌的质量和数量。通过测量脐水平处腰大肌的横截面积和平均 CT 值来计算腰大肌质量指数(PMI)和放射密度(RD),分别用于确定肌肉的数量和质量。本研究共纳入 186 例年龄在 17 岁至 68 岁(中位数,49 岁)的成年患者,其中 46 例(24.7%)患者被分到低 PMI 组,49 例(26.3%)患者被分到低 RD 组。低 RD 被确定为 allo-HSCT 后总体生存不良的独立危险因素(调整后的危险比[HR],2.54;P <.01),而 PMI 则无统计学意义。移植前 RD 降低和 6 分钟步行距离缩短是导致非复发死亡率增加的显著因素(HR,2.69;P =.01)。这项研究首次提出使用定性骨骼肌指数作为 allo-HSCT 后的预后指标。RD 应被纳入移植前筛查参数中,包括以改善肌肉质量和数量为重点的康复方法可能会改善 allo-HSCT 的预后。